3rd October 2024 • 0 comments

Ghana's implementation of the RTS,S malaria vaccine in 2019 has been evaluated in a retrospective study conducted in early 2024. Using an adapted WHO checklist, researchers assessed various aspects of the Malaria Vaccine Implementation Programme (MVIP) across 42 districts. The study aimed to provide a quantitative rating of the country's performance, addressing a gap in previous evaluations. Results showed an overall "good" performance score of 78.9%, with strengths in areas such as policy, coordination, and health worker training. However, challenges were identified in financial planning, cold chain management, and monitoring. These findings offer valuable insights for improving Ghana's immunization program and can guide other regions introducing malaria vaccines, regardless of the specific product used. The study highlights both the successes and areas for improvement in this pioneering public health initiative.

1st October 2024 • 0 comments

A recent study from Malawi offers promising insights into protecting school-age children from malaria. Researchers compared two approaches: treating all students (IPT) versus screening and treating only infected students (IST). While both methods successfully reduced malaria infections, only treating all students (IPT) lowered clinical malaria cases and anaemia. Interestingly, students receiving either treatment showed improved literacy scores. This research could be useful in malaria control in schools across Africa, potentially boosting both health and education outcomes. The study also successfully used tablet-based tests to measure cognitive skills, paving the way for future large-scale assessments in similar settings. Read the full article to learn how this approach could transform the fight against malaria in school-age children

22nd September 2024 • 0 comments

TGHN Malaria knowledge hub meet and greet session

by TGHN Malaria knowledge hub team
17th July 2024 • 0 comments

 Promising Results for New Malaria Vaccine in African Children A phase 3 clinical trial published in The Lancet provides strong evidence that a new malaria vaccine, R21/Matrix-M, is highly efficacious and safe in African children. The randomized controlled trial was conducted at sites across four sub-Saharan African countries from 2021-2022. Nearly 5000 children aged 5-36 months received three doses of the R21/Matrix-M vaccine or a control rabies vaccine.

26th February 2024 • 0 comments
8th February 2024 • comment

Cabo Verde eliminates malaria

by Gilbert Nakweya
8th February 2024 • 0 comments
28th January 2024 • 0 comments
4th December 2023 • 0 comments

Malaria in 2022: Increasing challenges, cautious optimism

by Prasanna Jagannathan, Abel Kakuru
23rd November 2023 • 0 comments
11th October 2023 • 1 comment
24th April 2023 • 0 comments

In this project from the International Centre of Insect Physiology and Ecology in Kenya and funded by the DELTAS Africa CPE Seed Fund, high school students were educated about malaria and scientific research, to inspire them to become ambassadors in their communities, and to go on to have careers in science.

26th August 2021 • 0 comments

The Amazon biome is under severe threat due to increasing deforestation rates and loss of biodiversity and ecosystem services while sustaining a high burden of neglected tropical diseases. Approximately two thirds of this biome are located within Brazilian territory. There, socio-economic and environmental landscape transformations are linked to the regional agrarian economy dynamics, which has developed into six techno-productive trajectories (TTs).

16th July 2021 • 0 comments

The authors aimed to estimate the cost-effectiveness of intermittent preventive treatment in pregnancy with dihydroartemisinin-piperaquine (IPTp-DP) versus IPTp-SP to prevent clinical malaria infection (and its sequelae) during pregnancy. Findings suggest that among HIV-negative pregnant women with high uptake of long-lasting insecticidal nets, IPTp-DP is cost-effective in areas with high malaria transmission and high sulfadoxine-pyrimethamine resistance. These data provide a comprehensive overview of the current evidence on the cost-effectiveness of IPTp-DP. Nevertheless, before a policy change is advocated, we recommend further research into the effectiveness and costs of different regimens of IPTp-DP in settings with different underlying sulfadoxine-pyrimethamine resistance.

16th November 2020 • 0 comments